Sun Pharma Baska facility gets OAI status from USFDA

Mumbai:  Sun Pharma has announced that the company has received Official Action Indicated (OAI) status from the U.S. Food and Drug Administration (USFDA) for Baska facility.

The USFDA conducted an inspection at the facility from 8 September 2025 to 19 September 2025.

OAI means regulatory and/or administrative actions are recommended.

“We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status,” the company stated in a BSE filing.

Sun Pharma is a specialty generics company with a presence in specialty, generics and consumer healthcare products. Sun Pharma’s global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. Its manufacturing facilities are spread across six continents.

Related Posts

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus board approved a buyback of up to Rs 1100 crore at Rs 1,150 per share, along with a 100 percent dividend for FY26. Zydus Lifesciences reported a rise in…

Chemists strike on May 20: Reasons behind today’s all-India strike

While major pharmacy chains and government medical outlets will remain operational, the strike highlights significant tensions within the industry that could impact access to medications nationwide. The All India Organisation…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Zydus Lifesciences Q4FY26 net profit rises 9%

Zydus Lifesciences Q4FY26 net profit rises 9%

Chemists strike on May 20: Reasons behind today’s all-India strike

Chemists strike on May 20: Reasons behind today’s all-India strike

AbbVie loses patent plea for Hep C drug

AbbVie loses patent plea for Hep C drug

GSK’s Calpol a well-known trademark: High Court

GSK’s Calpol a well-known trademark: High Court

3 arrested for allegedly posing as doctors using forged MBBS degrees

3 arrested for allegedly posing as doctors using forged MBBS degrees

Commissioner FDA reviews enforcement measures

Commissioner FDA reviews enforcement measures